Sodium ferulate

Catalog No.S4740 Batch:S474001

Technical Data

Formula	C₁₀H₉O₄.Na
Molecular Weight	216.17	CAS No.	24276-84-4
Solubility (25°C)*	In vitro	Water	43 mg/mL (198.91 mM)
		DMSO	2 mg/mL (9.25 mM)
		Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description	Sodium ferulate (SF, Ferulic acid sodium salt), the sodium salt of ferulic acid, is a drug used in traditional Chinese medicine for treatment of cardiovascular and cerebrovascular diseases and to prevent thrombosis.
In vitro	SF is stable, water soluble. In vitro, SF (0.4 mg/mL) inhibits platelet aggregation induced by adenosine diphosphate (ADP) or collagen. At 1 mg/mL SF inhibits thrombin-induced platelet aggregation and release of [3H]5-HT from labelled platelets. The mechanism of SF action appears to be mediated by inhibition of cyclooxygenase and TXA2 synthase. In vitro SF inhibits lipid peroxide malondialdehyde (MDA) production from the platelets of rats, inhibits haemolysis induced by MDA and hydroxyl radical (OH·), and in erythrocyte membranes it inhibits lipid peroxidation induced by hydrogen peroxide (H2O2) and superoxide anions (O₂^-). SF is a direct scavenger of oxygen free radicals. SF is found to act as a novel non-peptide endothelin antagonist and to prevent the binding of ET-1 to its receptor^[1].
In vivo	SF has antithrombotic, platelet aggregation inhibitory and antioxidant activities in animals and humans. In ethanol, carbon tetrachloride-, paracetamol-, or prednisolone-induced liver toxicity in mice, SF, 0.1 g/kg intragastrically, daily for 10 days inhibits the rise of liver lipid peroxides MDA content and alleviates liver lesions by stabilizing glutathione (GSH) and related enzymes levels. In glycerol-induced renal oxidative injury in mice, SF at 0.2 g/kg i.p., reverses the increase of renal MDA content and the decrease of GSH content, glutathione peroxidase (GSH-Px), glutathione S-transferase (GST), catalase (Cat), and SOD activities induced by glycerol injection, and improves renal histology. SF has a clear protective effect in experimental myocardial ischemia. In rabbits SF reduces the area of experimental myocardial infarction by 41% and decreases the oxygen consumption of guinea pig myocardial homogenates. SF has also a protective effect in myocardial ischemia reperfusion injury of rats. Furthermore, SF has an anti-atherogenetic effect in animal models. The antiarrhythmic effects of SF have been demonstrated in experimental animal models of arrhythmia, but not yet in clinical studies. The elimination half-life of SF is about 9.86 min. The acute oral LD50 of SF in mice is 3.2 g/kg^[1].

Protocol (from reference)

Cell Assay:^{^[2]}	Cell lines Cultured vascular smooth muscle cells (VSMCs) Concentrations 0, 50, 100 and 200 µmol/L Incubation Time 1 h Method 8,000 cells are seeded in each well of 96-well plate. After synchronous growth in DMEM including 0.5% FBS for 24 hours, VSMCs are pre-incubated in a variety of concentrations of sodium ferulate (0, 50, 100 and 200 µmol/L) for 1 hour and then stimulated with Ang Ⅱ (1 µmol/L) for another 48 hours. Following addition with CCK-8 reagent, OD values are measured at 450 nm using microplate spectrophotometer.
Animal Study:^{^[2]}	Animal Models Sprague-Dawley rats(Balloon injury model) Dosages 200 mg/kg Administration by gavage

Cell Assay:^{^[2]}

Cell lines
Cultured vascular smooth muscle cells (VSMCs)
Concentrations
0, 50, 100 and 200 µmol/L
Incubation Time
1 h
Method
8,000 cells are seeded in each well of 96-well plate. After synchronous growth in DMEM including 0.5% FBS for 24 hours, VSMCs are pre-incubated in a variety of concentrations of sodium ferulate (0, 50, 100 and 200 µmol/L) for 1 hour and then stimulated with Ang Ⅱ (1 µmol/L) for another 48 hours. Following addition with CCK-8 reagent, OD values are measured at 450 nm using microplate spectrophotometer.

Animal Study:^{^[2]}

Animal Models
Sprague-Dawley rats(Balloon injury model)
Dosages
200 mg/kg
Administration
by gavage

References

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.